About Us
Terms & Conditions
Privacy Policy
FAQ
Contact Us
Careers
Advertise
Download The App
Car Sticker
Community
Copyright © BFM Media Sdn Bhd (200601017962)
Play the Live Stream or select a Podcast to play
0:00
0:00
0:00
0:00
Play the Live Stream or select a Podcast to play
0:00
0:00
0:00
0:00
ADVERTISEMENT
morning-run · the-breakfast-grille · 14 Sept 2010 · 06:50 am · 21 mins listen
Peter Wulff, co-founder of Sentinext Theraputics, tells why the biotechnology company is banking on developing the vaccine for EV71, a virus that has been spreading in Asia. While incidences of deaths may be relatively low, survivors may suffer neural damage. The company needs to raise about $1 billion to bring the drug to the market. Currently it's funded by funds from the Malaysian government.
Related Content
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT